Shares of NRx Pharmaceuticals (NASDAQ: NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments . Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.
This morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.
Image source: Getty Images.
For further details see:Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday